Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04901260 · ClinicalTrials.gov registry record
AMAZE™ Asthma Implementation QI Study
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 117
- Enrollment target
NCT04901260 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 117 participants.
The verdict
NCT04901260 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 117 participants
- Enrollment target
Study Summary
The primary study objective is to generate evidence as to the feasibility, usability, perceived value, and potential benefits of implementing the AMAZE™ platform into clinical practice.
Interventions
- DEVICE AMAZE™ Disease Management Platform
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2020-11-25 |
| Est. Completion | 2021-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04901260
The ClinicalTrials.gov registry entry for NCT04901260 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMAZE™ Disease Management Platform is the first listed.
NCT04901260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04901260 about?
NCT04901260 is a clinical study titled "AMAZE™ Asthma Implementation QI Study". The primary study objective is to generate evidence as to the feasibility, usability, perceived value, and potential benefits of implementing the AMAZE™ platform into clinical practice.
What is the current status of trial NCT04901260?
This trial is currently completed. The enrollment target is 117 participants. The study started on 2020-11-25. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT04901260?
The interventions under investigation include: AMAZE™ Disease Management Platform (DEVICE).
Who is sponsoring clinical trial NCT04901260?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.